Patents Assigned to Caregen Co., Ltd
  • Patent number: 10487113
    Abstract: A peptide having activity to improve skin condition is described. The peptide exhibits a very excellent effect in improving skin condition by inhibiting MMP2 activity. A composition containing the peptide exhibits excellent biological activities, such as inhibiting collagen decomposition and melanosome migration, and thus can be used in wrinkle reduction, skin regeneration, skin elasticity improvement, anti-skin aging, wound regeneration, acne reduction, skin regeneration or skin whitening. The composition containing the peptide can be used as a pharmaceutical composition for preventing or treating MMP activity-related diseases and inflammation diseases.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: November 26, 2019
    Assignee: Caregen Co., Ltd.
    Inventors: Yong Ji Chung, Eun Mi Kim
  • Publication number: 20190270773
    Abstract: A peptide and a peptide complex of the present invention exhibit an anti-obesity effect by inhibiting fat accumulation and decomposing already accumulated fat, and exhibit an excellent effect with respect to diabetes by effectively reducing blood sugar. The peptide and the peptide complex of the present invention decrease the expression of PPAR?, ACC, and aP2, which are adipogenic markers, increase the expression of pHSL, AMPK-?1, CGI-58, and ATGL, which are lipolytic factors, and reduce the size of fat cells and blood cholesterol values. The peptide and the peptide complex of the present invention, which have excellent activity and safety, can be advantageously applied to drugs and quasi-drugs.
    Type: Application
    Filed: March 20, 2019
    Publication date: September 5, 2019
    Applicant: CAREGEN CO., LTD.
    Inventors: Yong Ji CHUNG, Eun Mi KIM
  • Publication number: 20190270772
    Abstract: A peptide and a peptide complex of the present invention exhibit an anti-obesity effect by inhibiting fat accumulation and decomposing already accumulated fat, and exhibit an excellent effect with respect to diabetes by effectively reducing blood sugar. The peptide and the peptide complex of the present invention decrease the expression of PPAR?, ACC, and aP2, which are adipogenic markers, increase the expression of pHSL, AMPK-?1, CGI-58, and ATGL, which are lipolytic factors, and reduce the size of fat cells and blood cholesterol values. The peptide and the peptide complex of the present invention, which have excellent activity and safety, can be advantageously applied to drugs and quasi-drugs.
    Type: Application
    Filed: March 20, 2019
    Publication date: September 5, 2019
    Applicant: CAREGEN CO., LTD.
    Inventors: Yong Ji CHUNG, Eun Mi KIM
  • Publication number: 20190270774
    Abstract: A peptide and a peptide complex of the present invention exhibit an anti-obesity effect by inhibiting fat accumulation and decomposing already accumulated fat, and exhibit an excellent effect with respect to diabetes by effectively reducing blood sugar. The peptide and the peptide complex of the present invention decrease the expression of PPAR?, ACC, and aP2, which are adipogenic markers, increase the expression of pHSL, AMPK-?1, CGI-58, and ATGL, which are lipolytic factors, and reduce the size of fat cells and blood cholesterol values. The peptide and the peptide complex of the present invention, which have excellent activity and safety, can be advantageously applied to drugs and quasi-drugs.
    Type: Application
    Filed: March 20, 2019
    Publication date: September 5, 2019
    Applicant: CAREGEN CO., LTD.
    Inventors: Yong Ji Chung, Eun Mi Kim
  • Patent number: 10351597
    Abstract: A peptide and a peptide complex of the present invention exhibit an anti-obesity effect by inhibiting fat accumulation and decomposing already accumulated fat, and exhibit an excellent effect with respect to diabetes by effectively reducing blood sugar. The peptide and the peptide complex of the present invention decrease the expression of PPAR?, ACC, and aP2, which are adipogenic markers, increase the expression of pHSL, AMPK-?1, CGI-58, and ATGL, which are lipolytic factors, and reduce the size of fat cells and blood cholesterol values. The peptide and the peptide complex of the present invention, which have excellent activity and safety, can be advantageously applied to drugs and quasi-drugs.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: July 16, 2019
    Assignee: CAREGEN CO., LTD.
    Inventors: Yong Ji Chung, Eun Mi Kim
  • Patent number: 10351598
    Abstract: The present invention provides peptides with an anti-obesity and/or anti-diabetic activity consisting of an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, and optionally modified at their C- or N-terminal ends.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: July 16, 2019
    Assignee: CAREGEN CO., LTD.
    Inventors: Yong Ji Chung, Eun Mi Kim
  • Patent number: 10344061
    Abstract: The present invention relates to peptides exhibiting hair growth promoting activity and/or melanin production promoting activity, a composition for ameliorating hair loss comprising one or both of the peptides as an active ingredient, a composition for promoting hair growth and/or hair restoration comprising one or both of the peptides as an active ingredient, a use of one or both of the peptides for ameliorating hair loss, a use of one or both of the peptides for promoting hair growth and/or hair restoration, a pharmaceutical composition for the treatment of melanin hypopigmentation comprising one or both of the peptides as an active ingredient, a cosmetic composition for the treatment of melanin hypopigmentation comprising one or both of the peptides as an active ingredient, and a use of one or both of the peptides for the amelioration and/or treatment of melanin hypopigmentation.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: July 9, 2019
    Assignee: CAREGEN CO., LTD.
    Inventors: Yong Ji Chung, Eun Mi Kim, Eung Ji Lee
  • Publication number: 20190192677
    Abstract: The present invention relates to a composition for preventing hair loss and, more specifically, to a compound having a structure in which Minoxidil and a peptide are chemically connected, and to a pharmaceutical composition or cosmetic composition for preventing hair loss or promoting hair growth comprising the compound. The compound having a structure in which Minoxidil and a peptide are chemically connected according to the present invention has not only excellent physiological activity such as hair loss reduction, hair growth promotion or cell growth promotion, but also excellent stability in water, and can therefore be useful as a composition for preventing hair loss and promoting hair growth.
    Type: Application
    Filed: August 4, 2017
    Publication date: June 27, 2019
    Applicant: CAREGEN CO., LTD.
    Inventors: Yong Ji CHUNG, Eun Mi KIM
  • Patent number: 10238710
    Abstract: Provided is a peptide, which has an anti-inflammatory activity and an activity for promoting osteogenic differentiation, formed from the amino acid sequence selected from the group comprising the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3. And provided is a peptide, which has a hair growth promoting activity, formed from the amino acid sequence selected from the group comprising the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2. A peptide formed from the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, according to the present invention, consequently shows an anti-inflammatory activity by inhibiting an inflammatory cytokine expression and proliferation of inflammatory cells, and consequently promotes osteogenic differentiation by increasing phosphorylation of PI3K, Smad1, Smad5 and Smad8, which contribute to osteogenesis, and by increasing ALP, OPG and BSP expressions.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: March 26, 2019
    Assignee: CAREGEN CO., LTD.
    Inventors: Yong Ji Chung, Eun Mi Kim, Eung Ji Lee, Kyoung Mi Cho, A Reum Han
  • Patent number: 10093698
    Abstract: A peptide formed from the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2 shows a melanogenesis increment activity and an adipogenesis inhibitory activity. The peptide, by increasing phosphorylation of MITF, which is a transcription factor for increasing a tyrosinase expression, and CREB for increasing an MITF expression, consequently increases a tyrosinase expression and ultimately increases melanin synthesis. The peptide, by reducing the amount of fat accumulated inside a cell and reducing expressions of perilipin and PPAR?, which contribute to adipogenic mechanism, ultimately inhibits adipogenesis. A composition for remedying or treating melanin hypopigmentation, a composition comprising the peptide, and a pharmaceutical composition for treating or preventing obesity, are provided.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: October 9, 2018
    Assignee: CAREGEN CO., LTD.
    Inventors: Yong Ji Chung, Eun Mi Kim, Eung Ji Lee, Kyoung Mi Cho
  • Patent number: 10080775
    Abstract: A peptide having skin-whitening activity is described. The peptide exhibits an excellent skin whitening effect by inhibiting melanogenesis, inhibiting the activity of tyrosinase, inhibiting the expression of melanosis-involved factors, and inhibiting melanosome transfer. The peptide has excellent skin permeability due to the small size thereof. Excellent activity and stability of the foregoing peptide can be very favorably applied to cosmetics.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: September 25, 2018
    Assignee: CAREGEN CO., LTD.
    Inventors: Yong Ji Chung, Eun Mi Kim, Eung-Ji Lee, Jan Di Kim
  • Patent number: 10047125
    Abstract: A peptide having activity to improve skin condition is described. The peptide exhibits a very excellent effect in improving skin condition by inhibiting MMP2 activity. A composition containing the peptide exhibits excellent biological activities, such as inhibiting collagen decomposition and melanosome migration, and thus can be used in wrinkle reduction, skin regeneration, skin elasticity improvement, anti-skin aging, wound regeneration, acne reduction, skin regeneration or skin whitening. The composition containing the peptide can be used as a pharmaceutical composition for preventing or treating MMP activity-related diseases and inflammation diseases.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: August 14, 2018
    Assignee: CAREGEN CO., LTD.
    Inventors: Yong Ji Chung, Eun Mi Kim
  • Patent number: 10000534
    Abstract: A peptide comprising an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, according to the present invention, shows proliferation and differentiation promotion of osteoblast and proliferation and activation promotion of periodontal ligament fibroblast. A peptide, according to the present invention, increases BMP signaling such as SMAD1/5/8 phosphorylation and increases the growth of osteoblast and the expression of a differentiation marker such as COL1A1, BSP and ALP, thereby ultimately showing osteoblast activation. A peptide, according to the present invention, promotes the growth of periodontal ligament fibroblast by means of PI3K and Akt phosphorylation and increases the expression of an activation marker such as COL1A1 and DSPP, thereby ultimately showing periodontal tissue regeneration activation. Provided are a composition for preventing or treating bone diseases and a composition for preventing or treating periodontal diseases, the compositions comprising the aforementioned peptide.
    Type: Grant
    Filed: August 5, 2014
    Date of Patent: June 19, 2018
    Assignee: CAREGEN CO., LTD.
    Inventors: Yong Ji Chung, Eun Mi Kim, Eung Ji Lee, A Reum Han, Hyun A Jung
  • Patent number: 9908916
    Abstract: The peptide of the present invention performs a function, which is the same as or similar to that of natural interleukin (IL)-3, and has superior skin permeability due to the small size thereof. In addition, the peptide of the present invention suppresses the activation of NF-?B and nuclear transition by inhibiting the receptor activator of nuclear factor kappa-B ligand (RANKL)-RANK signaling pathway, and suppresses the expression of a RANKL or an inflammatory cytokine-induced tartrate-resistant acid phosphatase (TRAP), cathepsin K, or TNF receptor type 1 or type 2, thereby inhibiting osteoclast differentiation depending on the treatment concentration. Moreover, the peptide of the present invention can contribute to osteoblast differentiation by promoting the expression of osteoblast differentiation markers such as osteocalcin (CON), osteoprotegerin (OPG), bone sialoprotein (BSP), or osteopontin (OPN).
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: March 6, 2018
    Assignee: CAREGEN CO., LTD.
    Inventors: Yong Ji Chung, Eun Mi Kim, Eung-Ji Lee, Tae-Hoon Lee, A Reum Han
  • Patent number: 9637519
    Abstract: A peptide according to the present invention can perform a function identical or similar to the function of natural CTLA-4 and has an excellent degree of skin penetration due to a small size. The peptide according to the present invention effectively binds to antigen presenting cell surface proteins (CD80 and CD86) to inhibit activity of T cells and thus is capable of inhibiting the expression of inflammatory cytokines (for example, IL-2 and IFN-?). As a result, a composition comprising the peptide according to the present invention exhibits excellent effects in terms of preventing, treating, or improving Th1-mediated immune diseases. Therefore, the superior activity and stability of the peptide according to the present invention can be useful when applied to medicine, quasi-drugs, and cosmetics.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: May 2, 2017
    Assignee: CAREGEN CO., LTD.
    Inventors: Young Ji Chung, Eun Mi Kim, Eung-Ji Lee, Tae-Hoon Lee, Young-Min Lee
  • Patent number: 9550078
    Abstract: The present invention relates to novel peptides derived from an EDAR (EDAR receptor) ligand which belongs to TNF (tumor necrosis factor)-? family and to uses of the same. The present peptides of EDA3 derived from EDA and EDphD1 derived from EDAR ligand possess identical or similar activities to naturally occurring EDA and have much higher stability and skin penetration potency than naturally occurring EDA. Therefore, the composition containing the present peptide not only shows excellent effects on improvement in hair loss and promotion of hair growth, but also has superior efficacies on treatment of an EDA signal transduction pathway-related disorder. In addition, the outstanding activity and stability of the present peptide described above may be greatly advantageous in application to pharmaceutical compositions, quasi-drugs and cosmetics.
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: January 24, 2017
    Assignee: CAREGEN CO., LTD.
    Inventors: Yong Ji Chung, Eun Mi Kim
  • Patent number: 9303064
    Abstract: A peptide inhibiting a matrix metalloproteinase activity, thereby improving the condition of skin and a composition containing the peptide is described, where the peptide comprises an amino acid sequence represented by the formula: Xaa1-Xaa2-Pro-Cys-Xaa3-Xaa4-Xaa5-Ser-Xaa6and has excellent bioactivities of inhibiting the activity of hyaluronic acid degrading enzymes, adipogenesis in fat cells, angiogenesis, and the like, thereby being useful for the treatment of various disease such as obesity, cancer, and inflammation.
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: April 5, 2016
    Assignee: CAREGEN CO., LTD.
    Inventors: Young Ji Chung, Eun Mi Kim
  • Patent number: 9295629
    Abstract: A WNT-derived peptide and use thereof are described. WNT-derived peptide of the present invention possesses identical or similar activities to natural-occurring WNT protein, and has much higher stability and skin penetration potency than natural-occurring WNT protein. Therefore, the composition containing the present peptide not only shows excellent effects on improvement in hair loss (for example, promotion of hair growth or production of hair), but also has superior efficacies on treatment of a WNT signal transduction pathway-related disorder. In addition, the outstanding activity and stability of the present peptide described above may be greatly advantageous in application to pharmaceutical compositions, quasi-drugs and cosmetics.
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: March 29, 2016
    Assignee: CAREGEN CO., LTD.
    Inventors: Yong Ji Chung, Eun Mi Kim
  • Publication number: 20160075739
    Abstract: A peptide according to the present invention can perform a function identical or similar to the function of natural CTLA-4 and has an excellent degree of skin penetration due to a small size. The peptide according to the present invention effectively binds to antigen presenting cell surface proteins (CD80 and CD86) to inhibit activity of T cells and thus is capable of inhibiting the expression of inflammatory cytokines (for example, IL-2 and IFN-?). As a result, a composition comprising the peptide according to the present invention exhibits excellent effects in terms of preventing, treating, or improving Th1-mediated immune diseases. Therefore, the superior activity and stability of the peptide according to the present invention can be useful when applied to medicine, quasi-drugs, and cosmetics.
    Type: Application
    Filed: October 25, 2013
    Publication date: March 17, 2016
    Applicant: CAREGEN CO., LTD.
    Inventors: Young Ji CHUNG, Eun Mi KIM, Eung-Ji LEE, Tae-Hoon LEE, Young-Min LEE
  • Patent number: 8969296
    Abstract: The present invention relates to a GFP-CAP peptide having an amino acid sequence derived from TGF-?1 (transforming growth factor-?1) and a cell adhesion sequence, wherein the amino acid sequence derived from TGF-?1 consists of the amino acid sequence of SEQ ID NO:1 and the TGFP-CAP peptide is represented by the following formula I: Ile-Trp-Ser-Leu-Asp-Thr-Gln-Tyr-Cell adhesion sequence (I). The TGFP-CAP peptide of the present invention exhibits excellent anti-angiogenic activity. In addition, the TGFP-CAP peptide of the present invention prevents effectively melanin generation in skin to have skin whitening effects. The present peptide shows much higher stability and permeability to skin than natural-occurring TGF-?1. Such plausible activities and safety of the present peptide enable advantageously to application to drugs, quasi-drugs and cosmetics.
    Type: Grant
    Filed: September 12, 2007
    Date of Patent: March 3, 2015
    Assignee: Caregen Co., Ltd
    Inventors: Yong-Ji Chung, Young Deug Kim, Eun Mi Kim, Jun Young Choi, Jin Seuk Kim, Sang Su Song, Kyoung Mi Cho